Why This Medical Device Company Is the Top Stock in the S&P 500 Today -- Barrons.com

Dow Jones01-13

By Nate Wolf

DexCom stock rose sharply Monday after the maker of glucose monitors reported better-than-expected preliminary results for the fourth quarter.

DexCom posted total revenue of around $1.26 billion for the quarter, up 13% from a year prior and above analysts' consensus estimate of $1.24 billion. The company also reiterated its guidance for 2025 adjusted gross profit margin of 61%.

Shares rose 6.7% to $71.95, putting the stock on pace for its highest close since last September, according to Dow Jones Market Data. It was the top stock in the S&P 500 on Monday.

DexCom anticipates total revenue of $5.16 to $5.25 billion in 2026, representing growth of roughly 11% to 13%. Adjusted gross margin is forecast to expand to 63% to 64%.

Investors will want more signs that the company is turning a corner when it reports its full financial results for the fourth quarter on Feb. 12. The earnings print comes after a 2025 when DexCom dealt with slowing growth and device reliability issues that a short seller claimed led to hospitalizations and patient deaths.

Write to Nate Wolf at nate.wolf@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

January 12, 2026 13:26 ET (18:26 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603528828?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 02:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603528828","market":"nz","top_or_hot":-1,"title":"Why This Medical Device Company Is the Top Stock in the S&P 500 Today -- Barrons.com","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nate Wolf \n</p>\n<p>\n  DexCom stock rose sharply Monday after the maker of glucose monitors reported better-than-expected preliminary results for the fourth quarter. \n</p>\n<p>\n  DexCom posted total revenue of around $1.26 billion for the quarter, up 13% from a year prior and above analysts' consensus estimate of $1.24 billion. The company also reiterated its guidance for 2025 adjusted gross profit margin of 61%. \n</p>\n<p>\n  Shares rose 6.7% to $71.95, putting the stock on pace for its highest close since last September, according to Dow Jones Market Data. It was the top stock in the S&amp;P 500 on Monday. \n</p>\n<p>\n  DexCom anticipates total revenue of $5.16 to $5.25 billion in 2026, representing growth of roughly 11% to 13%. Adjusted gross margin is forecast to expand to 63% to 64%. \n</p>\n<p>\n  Investors will want more signs that the company is turning a corner when it reports its full financial results for the fourth quarter on Feb. 12. The earnings print comes after a 2025 when DexCom dealt with slowing growth and device reliability issues that a short seller claimed led to hospitalizations and patient deaths. \n</p>\n<p>\n  Write to Nate Wolf at nate.wolf@barrons.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 13:26 ET (18:26 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why This Medical Device Company Is the Top Stock in the S&P 500 Today -- Barrons.com</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy This Medical Device Company Is the Top Stock in the S&P 500 Today -- Barrons.com\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-13 02:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nate Wolf \n</p>\n<p>\n  DexCom stock rose sharply Monday after the maker of glucose monitors reported better-than-expected preliminary results for the fourth quarter. \n</p>\n<p>\n  DexCom posted total revenue of around $1.26 billion for the quarter, up 13% from a year prior and above analysts' consensus estimate of $1.24 billion. The company also reiterated its guidance for 2025 adjusted gross profit margin of 61%. \n</p>\n<p>\n  Shares rose 6.7% to $71.95, putting the stock on pace for its highest close since last September, according to Dow Jones Market Data. It was the top stock in the S&amp;P 500 on Monday. \n</p>\n<p>\n  DexCom anticipates total revenue of $5.16 to $5.25 billion in 2026, representing growth of roughly 11% to 13%. Adjusted gross margin is forecast to expand to 63% to 64%. \n</p>\n<p>\n  Investors will want more signs that the company is turning a corner when it reports its full financial results for the fourth quarter on Feb. 12. The earnings print comes after a 2025 when DexCom dealt with slowing growth and device reliability issues that a short seller claimed led to hospitalizations and patient deaths. \n</p>\n<p>\n  Write to Nate Wolf at nate.wolf@barrons.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 13:26 ET (18:26 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4534","symbol_name":"瑞士信贷持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603528828","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603528828","pubTimestamp":1768242360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"DexCom stock rose sharply Monday after the maker of glucose monitors reported better-than-expected preliminary results for the fourth quarter.DexCom posted total revenue of around $1.26 billion for the quarter, up 13% from a year prior and above analysts' consensus estimate of $1.24 billion. The company also reiterated its guidance for 2025 adjusted gross profit margin of 61%.Shares rose 6.7% to $71.95, putting the stock on pace for its highest close since last September, according to Dow Jones Market Data. It was the top stock in the S&P 500 on Monday.DexCom anticipates total revenue of $5.16 to $5.25 billion in 2026, representing growth of roughly 11% to 13%. Adjusted gross margin is forecast to expand to 63% to 64%.Investors will want more signs that the company is turning a corner when it reports its full financial results for the fourth quarter on Feb. 12. The earnings print comes after a 2025 when DexCom dealt with slowing growth and device reliability issues that a short seller ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4534":"瑞士信贷持仓","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","UPRO":"三倍做多标普500ETF-ProShares","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","BK4082":"医疗保健设备","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","BK4504":"桥水持仓","BK4559":"巴菲特持仓","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","BK4588":"碎股","BK4550":"红杉资本持仓","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4548":"巴美列捷福持仓","DXCM":"德康医疗","SH":"做空标普500-Proshares","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","BK4551":"寇图资本持仓","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","OEX":"标普100","BK4581":"高盛持仓","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","IVV":"标普500ETF-iShares","SPXU":"三倍做空标普500ETF-ProShares","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","SDS":"两倍做空标普500 ETF-ProShares","OEF":"标普100指数ETF-iShares","SSO":"2倍做多标普500ETF-ProShares","BK4585":"ETF&股票定投概念"},"translate_title":"为什么这家医疗器械公司是当今标普500的顶级股票--Barrons.com","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SH":0.6,"UPRO":0.6,"MESmain":0.6,"OEX":0.6,"IVV":0.6,"DXCM":1.97,"SSO":0.6,"OEF":0.6,"ESmain":0.6,"SPXU":0.6,"SDS":0.6},"content_text":"By Nate Wolf \n\n\n  DexCom stock rose sharply Monday after the maker of glucose monitors reported better-than-expected preliminary results for the fourth quarter. \n\n\n  DexCom posted total revenue of around $1.26 billion for the quarter, up 13% from a year prior and above analysts' consensus estimate of $1.24 billion. The company also reiterated its guidance for 2025 adjusted gross profit margin of 61%. \n\n\n  Shares rose 6.7% to $71.95, putting the stock on pace for its highest close since last September, according to Dow Jones Market Data. It was the top stock in the S&P 500 on Monday. \n\n\n  DexCom anticipates total revenue of $5.16 to $5.25 billion in 2026, representing growth of roughly 11% to 13%. Adjusted gross margin is forecast to expand to 63% to 64%. \n\n\n  Investors will want more signs that the company is turning a corner when it reports its full financial results for the fourth quarter on Feb. 12. The earnings print comes after a 2025 when DexCom dealt with slowing growth and device reliability issues that a short seller claimed led to hospitalizations and patient deaths. \n\n\n  Write to Nate Wolf at nate.wolf@barrons.com \n\n\n   This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 12, 2026 13:26 ET (18:26 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603528828","isCrawlerRequest":true}